Tuberous Sclerosis: Medical Treatments

Department of Health and Social Care written question – answered on 5th November 2018.

Alert me about debates like this

Photo of Ben Bradley Ben Bradley Conservative, Mansfield

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure patients with refractory epilepsy related to tuberous sclerosis complex are able to access new medicines.

Photo of Steve Brine Steve Brine The Parliamentary Under-Secretary for Health and Social Care

Patients with tuberous sclerosis complex (TSC) have access to standard anti-epileptic drugs and whilst not licensed specifically for use in association with TSC, there is evidence that two thirds of patients will respond to treatment. A relatively new option specifically licensed for refractory epilepsy in TSC is everolimus (Votubia) which is due to be considered for prioritisation within the National Health Service in England in December as part of NHS England’s biannual relative prioritisation process for specialised services.

The life sciences sector deal, published last autumn, will ensure that the next wave of breakthrough treatments, innovative medical research and technologies are created in Britain. A key part of the deal was our commitment to improving patient access to innovation through the implementation of the Accelerated Access Review.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.